Related Experiment Videos
Effects of covalently bound silica-nitroimidazole drug particles on Entamoeba histolytica
D Mirelman1, F De Meester, T Stolarsky
1MacArthur Center for Molecular Biology of Parasitic Diseases, Rehovot, Israel.
Abstract:
Most commonly used antiamoebic drugs are effective in invasive amebiasis, but their response against trophozoites of Entamoeba histolytica, present in the lumen of the human colon, is inadequate. We report the development of an antiamoebic drug carrier that may be effective against luminal infections. Our preparation consists of small silica particles (5-10 microns in diameter) covalently linked to a potent antiamoebic drug, 2-(4-aminophenoxymethyl)-5-nitro-1-methyl imidazole. Silica-drug particles were injected into mice, hamsters, and guinea pigs. We found that trophozoites phagocytosed the particles in vivo and in vitro, followed by rapid cell death due to the released drug. Analysis of mouse serum revealed that no drug was absorbed from the intestine after placement of the drug-containing particles in the intestine. The antiamoebic activity of particles recovered from the intestine was almost fully retained. This novel antiamoebic concept may be useful for luminal therapy for asymptomatic amebiasis and may minimize side effects and frequency of administration.
Insights
A novel silica-drug carrier effectively targets Entamoeba histolytica in the colon. This targeted delivery system shows promise for treating luminal amebiasis with minimal drug absorption and retained activity.
Area of Science:
- Parasitology
- Drug Delivery Systems
- Nanotechnology
Background:
- Current antiamoebic drugs show inadequate efficacy against Entamoeba histolytica trophozoites in the colon lumen.
- Invasive amebiasis treatment is often effective, but luminal infections require different therapeutic strategies.
Purpose of the Study:
- To develop and evaluate a novel drug carrier system for targeted delivery of antiamoebic drugs to the colon lumen.
- To assess the efficacy of silica-drug particles against Entamoeba histolytica in vivo and in vitro.
Main Methods:
- Covalent linkage of an antiamoebic drug, 2-(4-aminophenoxymethyl)-5-nitro-1-methyl imidazole, to silica particles (5-10 microns).
- Administration of silica-drug particles to rodents (mice, hamsters, guinea pigs) and in vitro testing.
- Evaluation of trophozoite phagocytosis, drug release, cell death, and drug absorption from serum and recovered particles.
Main Results:
- Entamoeba histolytica trophozoites phagocytosed the silica-drug particles both in vivo and in vitro.
- Phagocytosis led to rapid trophozoite cell death mediated by the released antiamoebic drug.
- No significant drug absorption was detected in mouse serum, and particles retained antiamoebic activity after intestinal recovery.
Conclusions:
- Developed silica-drug particles demonstrate effective targeted delivery for luminal amebiasis therapy.
- This novel approach offers potential for treating asymptomatic amebiasis with reduced side effects and dosing frequency.
- The drug carrier system shows promise for localized treatment of intestinal parasitic infections.